Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m

Summary

The development of an innovative imaging agent capable of non-invasively detecting vulnerable plaques is a major objective of research in cardiovascular pathology. Such a tool would allow for better identification of patients at risk of acute events. We showed that 99mTechnetium (99mTc)-labeled fucoidan was able to target P-selectine expressed by activated platelets in vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and endocarditic vegetations in rats. One of the objectives of the Nanoathero program is the clinical translation of the 99mTc-fucoidan. As a first step, we will assess the safety, biodistribution and dosimetry of this new radiopharmaceutical in humans.

Timeline

Start

2018-02

Primary completion

2018-05

Completion

2018-07-31

Publications

• Oostveen RF, Zheng KH, Kaiser Y, Nurmohamed NS, Kroon J, de Wit TC, Poel E, Aerts J, Rouzet F, Stroes ESG, Letourneur D, Verberne HJ, Chauvierre C, Stahle MR. First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin. EJNMMI Res. 2024 Nov 19;14(1):112. doi: 10.1186/s13550-024-01173-8.

Drugs

Indications

No indication recorded.